{"slug":"second-cancer","tag":"second-cancer","variants":["second-cancer"],"description":"No description yet","count":2,"kinds":{"technology":2},"related":[{"slug":"rejuvenation","tag":"rejuvenation","shared":2},{"slug":"survivorship","tag":"survivorship","shared":2},{"slug":"transplant","tag":"transplant","shared":2},{"slug":"cell-therapy","tag":"cell-therapy","shared":1},{"slug":"late-effects","tag":"late-effects","shared":1}],"records":[{"id":"rejuv-tx-second-cancers","kind":"technology","name":"Second cancers after allogeneic transplant","route":"/technologies/rejuv-tx-second-cancers/","status":"established","tldr":"People who have had a donor transplant develop new, unrelated cancers about twice as often as people of the same age, and by fifteen years about three times as often. Radiation in the conditioning matters most for those irradiated young, and chronic GvHD raises squamous cancers of skin and mouth. Both point at lifelong screening."},{"id":"rejuv-tx-secondary-t-cell-malignancy","kind":"technology","name":"Secondary T-cell malignancy after CAR-T, and what the FDA's 2024 action actually says","route":"/technologies/rejuv-tx-secondary-t-cell-malignancy/","status":"established","tldr":"In 2024 the US regulator added a warning to every approved CAR-T product about T-cell cancers after treatment. It says the risk applies to the class, that these can appear within weeks, and that patients should be monitored for life. It does not say CAR-T causes most of them, and published series find them very rare."}]}